
Biofrontera (BFRI) Stock Forecast & Price Target
Biofrontera (BFRI) Analyst Ratings
Bulls say
Biofrontera Inc is poised for significant revenue growth due to the anticipated launch of new treatment indications for superficial Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027. The company's strategy of expanding its sales force, combined with favorable reimbursement policies that enhance Ameluz's market position over traditional cryotherapy, is expected to attract new customers to its photodynamic therapy offerings. Additionally, historical sales trends indicate that the fourth quarter will be crucial for revenue performance, especially with the recent update that allows increased dosing of Ameluz per treatment, potentially leading to higher sales volumes.
Bears say
Biofrontera Inc faces a negative outlook primarily due to its reported revenue of $8.6 million, which fell short of both estimates of $10.6 million and consensus predictions. Furthermore, the potential for regulatory surprises poses significant risks that could adversely affect revenue generation while also increasing operational costs. Lastly, the company's stock price is projected to decrease significantly, with expectations to align closer to a comp group average of 3x 2026 revenue, indicating concerns over its growth and execution capabilities.
This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.
Biofrontera (BFRI) Analyst Forecast & Price Prediction
Start investing in Biofrontera (BFRI)
Order type
Buy in
Order amount
Est. shares
0 shares